We used soluble, C-fixing antibody/dsDNA IC to investigate immune complex (IC) handling and erythrocyte (E)-to-phagocyte transfer in chimpanzees. IC bound efficiently to chimpanzee E in vitro and showed minimal release with further in vitro incubation in the presence of serum in EDTA (c 15% within 1 h). These IC also bound rapidly to E in vivo (70-80% binding within 1 min) and did not show detectable release from E in the peripheral circulation after infusion in vivo (< 2% within 1 h). Despite such slow C-mediated release of IC from E, IC were rapidly stripped from E by the mononuclear phagocyte system (T50 for E-IC1500 = 5 min) without sequestration of E. 
Introduction
Altered handling of immune complexes (IC)' is an important factor in the development of IC mediated disease. In experimental animals, saturation of clearance mechanisms or pro-longation of IC circulation times by various techniques can lead to increased IC deposition in target organs (1) (2) (3) (4) (5) (6) . The mononuclear phagocyte system (MPS) of liver and spleen provides the primary mechanism for IC disposal (5) (6) (7) (8) (9) . Circulating IC are removed by binding to receptors for the Fc portion of IgG and receptors for C3 fragments on the fixed tissue mononuclear phagocytes ofthis system (5, (8) (9) (10) (11) (12) . Recent work by Hebert (13) (14) (15) (16) and others (17) (18) (19) (20) , however, has emphasized the importance of complement (C) receptor type 1 (CRl)-mediated binding of circulating C-fixing IC to human and nonhuman primate erythrocytes (E). These observations suggest that E can act as a "buffer," which can bind C-fixing IC by way of CR1 and may decrease the probability of deposition of these IC in target tissues (21, 22) .
CR1-mediated E binding in primates (and a comparable platelet binding reaction in nonprimates [23] [24] [25] ) leads to the possibility that E may serve not only as a buffer by partitioning circulating IC to an E-bound pool but also as a delivery system, or "shuttle", which presents IC to the MPS for removal (26) .
From the perspective of an "erythrocyte shuttle", several questions become evident: (a) what are the determinants of the efficiency of binding to E; (b) is binding to an E a prerequisite for removal by the MPS; (c) are the fates of E-bound IC and non-E bound IC different; and (d) what are the mechanisms of transfer of IC from E to the MPS? Some information regarding these questions is available. For example, among the determinants of IC binding to E via CR1, the ability to fix C, the amount of C3b capture and the spatial organization of the captured C3b are important (25, 27) . Binding to E is not a prerequisite for efficient handling by the MPS (14, 25, 28) . Both model IC with rapid C-mediated release from E (tetanus/anti-tetanus toxoid and BSA/anti-BSA in vivo [13, 18] and in vitro [29, 30] ) and model IC with slow C-mediated release from E (Ab/dsDNA in vivo [24, 25] and in vitro [31] ) are cleared quickly by the MPS. These observations suggest that E binding may not fundamentally affect the rate of removal of IC by the MPS and that other properties of the IC or factors in the MPS must be significant.
To investigate the properties of the immune adherence reaction in IC handling in primates and to probe the nature of the E-to-phagocyte (MO) transfer mechanism, we performed a series of model IC infusion studies in chimpanzees. As a model IC system we used Ab/dsDNA IC because this antigen-antibody system is relevant to autoimmune disease (32, 33) , these model IC fix C efficiently and bind to E CR1 (34) (35) (36) , and their slow release from E allows for direct investigation of potential E sequestration during the IC transfer process. In addition to conventional clearance studies, we used anti-Fcy receptor MAb infusions to probe the role of Fcy receptors in the removal of soluble IC from the circulation by the MPS. Our data indicate that C-fixing Ab/dsDNA IC bind rapidly to of E or apparent release of IC into the circulation, and that an FcyR on the MO participates in the uptake of IC. These data, demonstrating that the transfer mechanism is much faster than C (Factor I) mediated spontaneous Preparation ofantibodies. The 7S IgG fraction of an SLE plasma (plasma Ma), which contains high titer nonprecipitating anti-dsDNA antibodies, was prepared as previously described (25, 35) . The IgG anti-dsDNA antibodies isolated from this plasma form soluble, C-fixing IC with dsDNA that bind to CR1 on human E (31, 36) . The biophysical and immunological properties ofthese IC have been extensively characterized both in vitro and in vivo in a number of animal systems (24, 25, 27, 28, 31, (34) (35) (36) .
3G8, a murine IgGI MAb recognizing human Fc-yRIII, was prepared by Damon Biotechnology (Needham Heights, MA). MOPC 21, a murine IgGl myeloma protein, was prepared as previously described (12) . Fab fragments were prepared by digestion with papain-Sepharose (Sigma Chemical Co., St. Louis, MO) and were purified by passage over protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) at pH 8.3 and by molecular sieve chromatography with a column of TSK 3000 (LKB Instruments, Inc., Rockville, MD). Proteins were > 95% pure, and Fab fragments contained no detectable heavy chains, as judged by silver stain of SDS-PAGE analytical gels. Preparations used for infusions were sterile and contained < 0.25 ng endotoxin/mg of total protein, as determined by the Limulus amebocyte assay (Associates of Cape Cod, Woods Hole, MA).
Preparation of radiolabeled dsDNA. Iodinated dsDNA was prepared and characterized before each experiment as previously described (24, 25) . Briefly, PM2 dsDNA, either intact (9,000 bp) or sonicated (800 bp), was radiolabeled with '25I-dCTP (New England Nuclear, Boston, MA) by nick translation. The sizes of the resulting '25I-labeled dsDNA preparations were 1,500±200 bp ("large dsDNA") and 500±100 bp ("small dsDNA"), respectively, as determined by 3.5% PAGE. The radiolabeled preparations ranged from 1,000 to 2,000 cpm/ng sp act. The '251-dsDNA preparations were 80-92% double-stranded as assessed by SI nuclease digestion (Bethesda Research Laboratories, Gaithersburg, MD) and > 95% precipitable in 5% TCA.
Preparation and characterization of soluble immune complexes.
The 7S IgG anti-dsDNA was titered with each DNA preparation to determine the amount of antibody required for maximal C-mediated binding (34) . These IC give > 90% binding in the Farr assay (38) . To insure that the dsDNA was saturated with anti-DNA antibodies, soluble IC for the in vivo experiments were prepared at a two-to threefold higher Ab/dsDNA ratio (27, 35) . IC made with dsDNA of 500 bp are typically 50-100 S in size (34) .
For experiments with IC released in vitro from chimpanzee E (see below), the relative sizes ofthe dsDNA antigen in different IC preparations were checked by submarine gel electrophoresis in 1% low endoosmotic agarose. Gels were visualized directly under ultraviolet light and then autoradiographed with Kodak XAR film. No differences in the size of the dsDNA antigen from the initial IC preparation relative to that from the released preparation could be detected.
Preparation oferythrocytes for in vitro and in vivo use. E, isolated from heparinized whole blood, were washed twice with PBS-10 mM EDTA and three times with PBS containing 0.15 mM CaCl2 and 0.5 mM MgCl2 (PBS+2). Chromium labeled E were prepared by incubating an aliquot of 25% (vol/vol) autologous E with 0.5 mCi of 5"Cr for 30 min at 37°C. The radiolabeled E were subsequently washed three times and resuspended at a concentration of 25% in PBS+2.
Immune complex binding to primate erythrocytes in vitro. For quantitative binding of IC to chimpanzee E or human E in the presence of autologous serum C, washed E were incubated with subsaturating concentrations of freshly prepared IC for 20 min at 37°C (34) . This procedure typically yielded > 85% bound and 10-20 IC per E. After one wash with PBS+2 to remove unbound IC and the addition of fresh serum in EDTA (as a source of C), the release reaction was assessed by the time-dependent appearance of unbound IC in the supernatant (39) . To assess possible C-independent binding to chimpanzee E, aliquots of E, 7S anti-DNA IgG and labeled dsDNA were incubated with heat-inactivated serum. Negligible binding (< 10%) occurred under these conditions. Similarly, '251-dsDNA mixed with fresh serum C did not bind to E in the absence of antibody.
Experimental protocolsfor handling ofsoluble IC. For each in vivo experiment IC were freshly prepared according to one offour protocols from titered stocks of anti-dsDNA IgG and radiolabeled dsDNA. (a) For direct in vivo infusions of soluble C-fixing IC, predetermined amounts of 7S IgG anti-dsDNA and '251I-dsDNA were mixed and incubated for 1 h at 37°C just before intravenous injection. (b) For IC bound in vitro to autologous E, freshly prepared soluble IC were incubated for 20 min at 37°C with a 25% suspension of5Cr-labeled chimpanzee E and fresh autologous serum C. After one wash with PBS, these "IC-loaded" E were injected immediately. (c) To obtain "released complexes" an aliquot of "IC-loaded" E was further incubated with fresh autologous serum as a C source and actively mixed for 3-4 h at 37°C. The resultant supernatant, containing the released IC, was harvested and injected intravenously. Under these conditions this procedure yielded 40-60% release of IC from E. (d) Finally, IC were prepared in vitro to contain large amounts of human C3d,g fragments ("partial d,g IC") as previously described (31) . Ab/3H-dsDNA IC were opsonized with human C and allowed to bind to human E. The IC were then released from the E by overnight incubation in serum at 37°C. These released IC (containing C3d,g) were treated with DNAse and then 50% SAS to recover the C3d,g-containing anti-dsDNA IgG. These Ab formed IC with fresh dsDNA (as detected in the Farr assay) that did not bind significantly to human E in the presence or absence of fresh human C (typically < 25%). This IgG preparation was then used according to protocol a.
The IC were injected into an antecubital vein in < 5 s. Blood samples (5.0 ml) were then drawn from the opposite arm every 30 s in initial experiments (every minute in later experiments) for the first 3 min, then at 5, 7.5, 10, 20, 30, and 60 min. Saline or MAb 3G8 (0.8 mg/kg) was then infused over 30 min and a second clearance study with an identical protocol was performed. Initial experiments indicated that the first study did not alter subsequent clearance studies ( Each 5.0-ml sample of blood was immediately heparinized, put on wet ice, and centrifuged at 2,000 rpm for 4 min. The cell pellet, containing both E and leukocytes, was rapidly resuspended in iced PBS, centrifuged again, and separated from the supernatant. This processing ofthe pellet was complete within 10 min. As a control for time-dependent release of IC from E after phlebotomy but before completed sample processing, selected duplicate specimens were set aside for 30 min on wet ice and then processed in the usual fashion. No detectable release of the bound IC was observed. Finally, selected blood specimens were separated on single density Percoll to confirm that the IC were bound to the E (13, 19) .
The supernatant harvested from the washed cell pellet was combined with the initial iced plasma supernatant for each sample. Aliquots (1.0 ml) were mixed with one-half volume of 15% TCA at room temperature to precipitate intact dsDNA (immune complexed or free).
Saturated ammonium sulfate (SAS) was added to a second 1.0-ml aliquot for a final concentration of 40% vol/vol on wet ice to precipitate immune complexed '251-dsDNA. After centrifugation at 5,000 rpm for 20 min, the supernatants and precipitates were harvested and counted separately. A third measured aliquot of the plasma plus wash supernatant was saved and counted directly.
Experimental protocol for handling ofIgG-opsonized erythrocytes (12) . Chimpanzee E were chromium labeled and sensitized with an amount of chimpanzee anti-AcBcDc antiserum sufficient to yield 20,000 molecules of IgG per E. After intravenous injection of opsonized cells, blood samples were obtained from the opposite arm at 3, 5, 15, 30, 60, 90, and 120 min. A second study with freshly opsonized E was performed after infusion of MAb 3G8.
Data analysis in the soluble IC experiments. For each blood sample the counts for each fraction (cell pellet; TCA supernatant and TCA pellet; SAS supernatant and SAS pellet; unaltered plasma) were combined to derive total sample counts. The sum of both TCA fractions, both SAS fractions and the unaltered plasma fraction was designated "non-E bound"; the cell pellet was designated "erythrocyte bound" since Percoll density gradient analysis indicated that essentially all counts were associated with the E fraction. The non-E bound but TCA precipitable IC were calculated by the following formula: [TCA pellet/ (TCA supernatant + TCA pellet)] X total non-E bound counts. The same calculation was used to determine the SAS precipitable non-E bound IC. The total TCA (or SAS) precipitable counts were defined as the sum of both the TCA (SAS) precipitable non-E bound counts and the E bound counts; this calculation assumes that all E bound counts would be precipitable in solution (24, 25) . For the double label experiments, absolute counts per minute were corrected for spectral overlap of the two isotopes.
For clearance studies, each curve represents the mean (±SD) of all animals for each experimental condition. The clearance curves, both before and after MAb 3G8 infusion, were analyzed for the time required for the clearance of 50 and 75% ofthe E bound (or non-E bound TCA precipitable) counts (T50 and T75, respectively) relative to the counts present at 1 min in the appropriate fraction. In addition, we calculated the recovery of counts in the circulation based on the total counts infused and on the estimated blood volume of the animal. Typically, at 1 min, 75-85% ofthe total infused counts were present in the circulation.
Results
Antibody/dsDNA complexes in the chimpanzee model system Binding ofIC to chimpanzee erythrocytes in vitro. Human 7S IgG anti-DNA/dsDNA IC made with large DNA (-1,500 bp [IC 1,50]) bind efficiently to human E in a C-dependent fashion (31, (34) (35) (36) . Similarly, > 80% of model IC made with larger DNA (-3,000 bp) bind E from rhesus monkey when assayed in vitro and tested in vivo (19) . To confirm C-mediated IC binding to chimpanzee E, IC made with '25I-labeled dsDNA (both IC1,500 and IC prepared with small dsDNA of -500 bp [IC500]) and 3H-labeled intact PM2 dsDNA were incubated with autologous serum as a source of C and an excess of E for 20 min at 37°C. Efficient binding to chimpanzee E was evident for all three dsDNA preparations (Table I) . Only 15% of the IC were released from chimpanzee E within 60 min after the addition of fresh C in EDTA. These data indicate that IC containing large dsDNA IC bind efficiently to chimpanzee E in vitro and in addition that the in vitro C-mediated release reaction for these large IC from chimpanzee E is slower than it is for human E.
Partitioning of soluble IC to erythrocytes in vivo. Large, soluble antibody/dsDNA IC (ICf.I c)showed rapid binding to the chimpanzee E after intravenous infusion. More than 50% of circulating IC were bound within 15 s and -70% were bound by 1 min, whereas native DNA (both -1,500 bp and -500 bp) showed minimal binding (< 6%) to E (Fig. 1 ). These findings are consistent with observations of rapid binding to E ofsimilar Ab/dsDNA IC in baboons (16) and in rhesus monkeys (19) , of very large anti-BSA/BSA IC in baboons (13) , and of tetanus/antitetanus toxoid IC in humans (18) .
In attempts to generate IC that would not bind to the E in vivo, we decreased the size of the dsDNA (34), used IC harvested from E after serum-mediated release (31) , and generated IC partially opsonized with the human C degradation (Fig. 1 ) and is cleared from the circulation with an initial half-time of 10-15 min (Fig. 2 A) . This clearance rate is substantially slower than that found in nonprimates (half-time of 1-2 min; [19, 25] ) but is comparable to that found in other primates (16, 19) . Formation of IC with dsDNA altered the handling of the DNA. Most IC1,500 became bound to E in vivo and were cleared more rapidly than free DNA alone while non E-bound IC were cleared more slowly than free DNA alone. IC500 showed slower clearance, whether E-bound or non-E bound, than free DNA (Fig. 2, B and C) . Interestingly, the clearance rate of E-bound IC1s500 was slower when soluble IC1,500 was infused directly than when IC1,500 was bound to E in vitro before infusion (see Fig. 2 Disposition of in vitro erythrocyte bound antibody/dsDNA immune complexes. In several IC model systems, IC release rapidly from E after initial C-mediated binding. Both anti-BSA/BSA and tetanus/antitetanus toxoid IC show a rapid return to fluid phase in vitro (29, 30) . This rapid release has also been sought and demonstrated in vivo with tetanus/antitetanus toxoid IC (18) . Ab/dsDNA IC do not show rapid release in vitro (Table I) , and therefore, experiments were designed to test for the occurrence ofthe release reaction in vivo. IC were bound to autologous E in vitro and these IC-loaded E alone were infused (Fig. 3 A, open circles) . No detectable release of IC into a non-E bound fraction was found in the circulation (< 1% during the first 10 min and < 2% over 1 h; Fig. 3 B, open circles) .
Given the lack of detectable release of Ab/dsDNA IC from E into the circulation, we tested the possibility that these ICopsonized E would be sequestered by the MPS like E opsonized with anti-E IgG (12) . Previous investigators attempting to address this question have looked for a change in the total body E mass rather than at the specific fate of those E opsonized with IC (13) . Using double radiolabel techniques we examined the fate of the 5'Cr-labeled E opsonized with 10-20 '25l-labeled IC per E. Fig. 4 IC1,500 bound to chimpanzee E in vitro were cleared very rapidly after intravenous infusion (initial T50 of 5 min, Figs. 3 A and 4). Since control studies with infused saline showed that neither ketamine anesthesia nor a prior clearance study prolonged the clearance of additional soluble IC (Fig. 5 A) , additional studies with ICI,500 prebound to E in vitro were performed. Infusion of MAb 3G8 IgG, 0.8 mg/kg, did not alter the earliest phase ofthe curve but did induce a modest impairment of IC1,500 removal after 7.5 min (Fig. 3 A, closed circles).
More striking, however, was the appearance of significant amounts of both circulating non-E bound TCA precipitable and non-E bound SAS precipitable IC after anti-FcyR MAb infusion. In contrast to the pretreatment experiments ( Fig. 3 B , open circles), clearly measurable free IC1,500 were apparent at every time point after MAb infusion (Fig. 3 B, closed circles) . This phenomenon is unlikely to be due to Factor I-mediated release of IC from E in the periphery (due to prolonged circulation) since it was evident during the first 7.5 min both when the pre-and posttreatment E-bound IC clearance curves were superimposable. Rather, it would appear that the anti-Fc'YR MAb was interfering with the ability of fixed tissue mononuclear phagocytes to take up and/or retain large, C-fixing IC1,500
after their release from E.
Effect of anti-FcyRIII on infused soluble IC. Infusion of
MAb 3G8 IgG (0.8 mg/kg), or MAb 3G8 Fab (0.6 mg/kg) did not alter the earliest phase of the in vivo E-bound IC500 clearance curve but did induce a modest impairment of removal after 7.5 min (Fig. 5 B and C, respectively) . However, when the non-E bound TCA precipitable IC500 are examined, it can be seen that MAb 3G8 IgG did produce a large impairment in clearance (Fig. 5 E) . When MAb 3G8 Fab was infused, no consistent change in the handling of the non-E bound IC fraction was seen (Fig. 5 F) . We attribute this observation to unexplained factors since one animal in this experimental pair showed an acceleration ofclearance. The other animal showed a significant prolongation in the clearance of the non-E bound IC fraction after MAb 3G8 Fab infusion (pre-MAb 3G8 T50
= 80 min, post-3G8 T50 = 200 min) similar to that induced by MAb 3G8 IgG.
Discussion
Recent investigations have focused on E CR1 and the role of the immune adherence reaction, originally described in 1953 by Nelson for IC (42) , in the handling of circulating IC. A number of studies have carefully documented decreased numbers of CR1 on E from patients with autoimmune disease (43) (44) (45) and have shown decreased binding capacity for IC by such E even in the face of large E CR1 excess (46) . While directing attention to the potential for E to partition IC into a bound pool unavailable for tissue deposition, these studies 966 Kimberly, Edberg, Merriam, Clarkson, Unkeless, and Taylor have not addressed the mechanism of IC uptake by fixed tissue phagocytes. To explore some of the mechanisms involved in IC uptake, both for the transfer of E-bound IC to MO and for the direct uptake of non-E bound IC by MO, we performed a series of model IC infusion studies in chimpanzees. Our data indicate that transfer from E to MO proceeds rapidly and much faster than Factor I-mediated release of IC from E both in the circulation and in vitro (Fig. 4, Table I ). Blockade ofthe ligand binding site of FcyRIII alters the handling of E-bound and non-E bound IC (Fig. 5) . Taken together, these data indicate that the interaction of IC and E-IC with fixed tissue phagocytes involves qualitatively different mechanisms than the interaction of IC with E CR 1.
The Ab/dsDNA IC were chosen as a model antigen-antibody system because these IC are relevant to autoimmune disease (32, 33) , they have well-characterized immunochemical properties and their behavior has been studied in human, primate, rabbit, and mouse models (24, 25, 27, 28, 31, (34) (35) (36) . These IC fix C efficiently, bind avidly to primate E via CR1 and release slowly from human E in the presence of Factor I (Table I) . These Ab/dsDNA IC are unlike previously studied BSA/anti-BSA and tetanus/antitetanus toxoid IC which show more rapid release from E in the presence of Factor I (18, 29, 30) . This important difference in the kinetics of release precludes the use of these latter two model IC systems for the investigation of several critical questions including sequestration of IC-opsonized E by the MPS and retention of IC by MO Fc receptors.
Specific examination of the Ab/dsDNA IC model system in chimpanzees revealed in vitro properties analogous to those documented in humans and other animals (Table I) . When infused in vivo (Figs. 1 and 2), these model IC behaved similarly to those infused into baboons, rhesus monkeys, rabbits, and mice (16, 19, 24, 25, 28) . As in the baboon, E-bound IC1,500 were cleared more rapidly in chimpanzee than free dsDNA alone while E-bound IC500 were cleared more slowly than free dsDNA. The higher binding levels of IC to chimpanzee E (and slower release in vitro) probably reflect a higher density of CR1 per E as suggested by increased levels of binding of monoclonal anti-CR 1 antibody E 1. Efficient uptake of non-E bound IC occurred for both types of IC. Interestingly, free dsDNA alone was cleared much more slowly in chimpanzee (and in other primates [ 16, 19] ) than in several nonprimate species (19, 25, 47) .
Mechanism ofIC transferfrom erythrocytes to M)
IgG-opsonized E are sequestered by the MPS in both humans (10) and chimpanzees (12) . Given the slow Factor I-mediated release of Ab/dsDNA IC from chimpanzee E, we examined whether a similar sequestration of IC-opsonized E would occur. Previous experimental approaches to (Fig. 4) .
The mechanisms underlying this highly efficient stripping of E, however, remain incompletely defined. It has been proposed that the transfer of IC from E to MO involves the proteolytic cleavage of the E CR1 (48, 49 Fab fragments, induced a modest impairment in the clearance of E-bound model IC (Fig. 3 A and Fig. 5 ). More apparent was the effect on the handling of non-E-bound IC, which may have captured less C3b (Fig. 5) . These An approach to this question can be made using IC bound to E in vitro to formulate the experimental framework (Fig. 6) . One model of IC transfer would require rapid release ofthe IC from the E upon entry of the E-IC into the hepatic environment followed by engagement ofthe IC in a non-E-bound state by the MO (Fig. 6 A) . However, no evidence for Factor I-mediated release of IC from E could be found in our experiments (Fig. 3 B) . If one assumes that the MO encounters the IC directly in the E-bound state (Fig. 6 B) as suggested by the work of Robineaux more than 25 years ago (55) , then rapid stripping would occur as a consequence of physical engagement of the E-IC by the Mo. If blockade of FcyRIII interferes with this engagement, the clearance of E-bound IC would be prolonged without the generation of stripped, non-E bound IC. If blockade of FcyRIII did not interfere with engagement but did impair Fc receptor-mediated retention ofthe IC on the M) cell surface, this would lead to stripped, non-E bound IC in the circulation. In order to examine this specific question, we looked for the appearance of TCA-precipitable and SASprecipitable IC (bound to E in vitro) in the circulation after MAb infusion (Fig. 3) . At every time point, both when the preand posttreatment E IC clearance curves were superimposable and when they were divergent, significant levels of non-E bound IC1,50s appeared in the circulation after MAb 3G8 infusion. Given the "direct contact" model of transfer, it would appear that retention of the IC after stripping from the E (and presumed chemical modification of the IC [29] and/or E-CRl [48, The relative contribution to clearance of the IC by each receptor system will depend upon the specific immunochemical properties of the IC. For example, IC that fix C but do not capture sufficient C3b (27) will be handled more by Fc receptors. The number of expressed receptors, their spatial grouping (56) and their intrinsic properties (perhaps reflecting allelic polymorphisms; Salmon, J. E., J. C. Edberg, and R. P. Kimberly. Manuscript submitted for publication.) will also contrib-ute to the relative role of each system. Genetically determined differences in receptor structure (57, 58) , expression (59) and function (60, 61) , and acquired differences in expression and display may be important in determining net function. For example, patients with SLE show both defects in C and Fc receptor dysfunction which can vary with disease activity (1 1, 62) . Further understanding of all of the components of the IC transfer and uptake mechanism will provide the insight necessary to identify critical pathogenetic mechanisms and to potentially manipulate them to advantage.
